loader
Please Wait
Applying Filters...

Seqens Seqens

X

Approved Drug Products containing 212268 listed in the FDA Orange Book. Original Data : FDA Website

Client Virtual Booth
Menu
Left Arrow
Right Arrow
Filters Filter
Cross PopUp
FILTER :

filter

01 HISAMITSU (3)

filter

01 SYSTEM;TRANSDERMAL (3)

filter

01 RX (3)

filter

01 SECUADO (3)

filter

01 Yes (3)

URL Supplier Web Content
SYSTEM; TRANSDERMA...
5.7MG/24HR
2019-10-11
212268
SECUADO
RX
Yes
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
SYSTEM; TRANSDERMA...
7.6MG/24HR
2019-10-11
212268
SECUADO
RX
Yes
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
SYSTEM; TRANSDERMA...
3.8MG/24HR
2019-10-11
212268
SECUADO
RX
Yes
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Looking for FDA Orange Book APPLICATION 212268

Looking for FDA Orange Book APPLICATION 212268 3

19

Hisamitsu Pharmaceutical Co., Inc., based in Japan, is a pharmaceutical company that stands out with its certifications from FDA.

One of their notable products is ASENAPINE, with a corresponding application number 212268.

Regulatory Information RX

With a dosage strength 5.7MG/24HR

Dosage Form Route SYSTEM; TRANSDERMAL

Reference Listed Drug Yes

Approved since 2019-10-11

18

Hisamitsu Pharmaceutical Co., Inc., based in Japan, is a pharmaceutical company that stands out with its certifications from FDA.

One of their notable products is ASENAPINE, with a corresponding application number 212268.

Regulatory Information RX

With a dosage strength 7.6MG/24HR

Dosage Form Route SYSTEM; TRANSDERMAL

Reference Listed Drug Yes

Approved since 2019-10-11

17

Hisamitsu Pharmaceutical Co., Inc., based in Japan, is a pharmaceutical company that stands out with its certifications from FDA.

One of their notable products is ASENAPINE, with a corresponding application number 212268.

Regulatory Information RX

With a dosage strength 3.8MG/24HR

Dosage Form Route SYSTEM; TRANSDERMAL

Reference Listed Drug Yes

Approved since 2019-10-11

Post Enquiry
POST ENQUIRY